Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat in PH and HFpEF (DYNAMIC)
NCT02744339Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Mar 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of riociguat in pulmonary hypertension (PH), heart failure with preserved ejection fraction (HFpEF), sponsored by Medical University of Vienna. Started Mar 2016; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT02744339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02744339.